Mr. Pink's Picks: selected event-driven value investments Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mr. Pink's Picks: selected event-driven value investments

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RockyBalboa who wrote (13602)	7/9/2000 11:31:44 AM
From: luis a. garcia	of 18998

isn't great though... if you guys are as good as I think you are and can really do due diligence you can cut through that lawyer bs and realize that is why the ticket prize is now 3.50 and that is your advantage. fact is that smith kline has partnered with avn for the otc distribution in us and canada. fact is skh made them a very good offer and is paying nice royalties as compared with customary. rumor is that the label is done and we will hear aobut it soon... and six months from hence there will be comercials and distribution nationwide of this cream. fact is avn has 11mill in cash and will get 25 more...in three chunkx fact is they will launch clinicals for genital herpes with these royalties.. then we are looking three yrs of increasing revenues.. docosanol otc fda approved us andcanada docosanol otc and rx GLOBAL plus milestones... docosanol rx herpes GLOBAL (actually off label otc...works as well but it wont be sold that way.. fda keeps track of these diseases etc... so they want rx for genital). then there is the other product monoclonal antibody mice with high affinity and specificity... a process that is faster and better than both medarex and abgenix put together. Because it helps identify the best monoclonal candidates sooner... now medx and abgnx are trading for 90 & 100+ so as avn moves to new bld in sept with new mice labs etc they will launch that biz. so if that is not enough there are two more major drugs in pipeline they can launch clinicals on at some point. Summary the company has new blockbuster otc drug with partner... will end up with 35 mill in cash will launch blockbuster mice biz in the fall will go genital clinical with or without partner and has a pipeline to boot... and its trading for 3.50 a share... hey I want you guys to slap me silly and show me a better deal... I mean it.... my money is important to me...I can not waste it... luis

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next